

DATES: We must receive your comments on or before June 30, 2002.

ADDRESSES: Address all comments about the guidelines to the Office of the Chief Information Officer, General Services Administration, 1800 F St., NW., room 3245, Washington, DC 20405.

If you prefer to send your comments through the Internet, use the following e-mail address: section515@gsa.gov.

You must include the term "Section 515 Information Quality Guidelines" in the subject line of your electronic message.

FOR FURTHER INFORMATION CONTACT: For a Copy of the Guidelines and Further Information: The guidelines are available through the Internet at the following site: http://www.gsa.gov/Portal/content/offering_content.jsp?contentOID=121870&contentType=1004&P=1&S=1. Alternatively, you may contact Jane Morgan, General Services Administration, 1800 F St., NW., room 2213, Washington, DC 20405. Telephone: (202) 501-2907. If you use a telecommunications device for the deaf (TDD), you may call the Federal Information Relay Service (FIRS) at 1-800-877-8339. Individuals with disabilities may obtain this document in an alternative format (e.g., Braille, large print, audiotape, or computer diskette) on request to the contact person listed under For a Copy of the Guidelines and Further Information.

SUPPLEMENTARY INFORMATION:

Invitation to Comment

We invite you to submit comments regarding the guidelines. During and after the comment period, you may view all public comments about these guidelines at the following site: http://www.gsa.gov/Portal/content/offering_content.jsp?contentOID=121870&contentType=1004&P=1&S=1.

Assistance to Individuals With Disabilities in Reviewing the Rulemaking Record

On request, we will supply an appropriate aid, such as a reader or print magnifier, to an individual with a disability who needs assistance to review the comments or other documents in the public record for these guidelines. If you want to schedule an appointment for this type of aid, please contact the person listed under For a Copy of the Guidelines and Further Information.

Electronic Access to This Document

You may view this document in text form at the following site: http://www.gsa.gov/Portal/content/offering_content.jsp?contentOID=121870&contentType=1004&P=1&S=1.

[offerings_content.jsp?contentOID=121870&contentType=1004&P=1&S=1](http://www.gsa.gov/Portal/content/offering_content.jsp?contentOID=121870&contentType=1004&P=1&S=1).

Note: The official version of this document is the document published in the **Federal Register**. Free Internet access to the official edition of the **Federal Register** and the Code of Federal Regulations is available on GPO Access at: <http://www.access.gpo.gov/nara/index.html>.

L. Diane Savoy,

Director, Office of Policy and Plans.

[FR Doc. 02-13757 Filed 5-31-02; 8:45 am]

BILLING CODE 6820-34-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Toxic Substances and Disease Registry

[ATSDR-182]

Availability of Draft Guidance Manual and Draft Interaction Profiles

AGENCY: Agency for Toxic Substances and Disease Registry (ATSDR), Department of Health and Human Services (HHS).

ACTION: Notice of availability.

SUMMARY: This notice announces the availability of a draft guidance manual and six draft interaction profiles prepared by ATSDR for review and comment.

DATES: To ensure consideration, comments on these draft documents must be received on or before September 2, 2002. Comments received after the close of the public comment period will be considered at the discretion of ATSDR based upon what is deemed to be in the best interest of the general public.

ADDRESSES: Requests for copies of the draft interaction profiles should be sent to the attention of Ms. Franchetta Stephens, Division of Toxicology, Agency for Toxic Substances and Disease Registry, Mailstop E-29, 1600 Clifton Road, NE, Atlanta, Georgia 30333.

Requests for the draft interaction profiles must be in writing, and must specifically identify the interaction profile(s) that you wish to receive. The documents will be primarily available in electronic Adobe Acrobat (pdf) files. If you do not have a computer, you can ask for a hard copy. ATSDR reserves the right to provide only one copy of each profile requested, free of charge. In case of extended distribution delays, requestors will be notified.

Interaction profiles and the guidance manual will also be available on

ATSDR's Web site at <http://www.atsdr.cdc.gov>.

Written comments and other data submitted in response to this notice and the draft interaction profiles or draft guidance document should bear the docket control number ATSDR-182. Send one copy of all comments and three copies of all supporting documents to Dr. Hana Pohl, ATSDR, Division of Toxicology, Mailstop E-29, 1600 Clifton Road, Atlanta, Georgia 30333 by the end of the comment period. Because all public comments regarding ATSDR interaction profiles and the guidance manual are available for public inspection after they are published in final, no confidential business information or other confidential information should be submitted in response to this notice.

FOR FURTHER INFORMATION CONTACT: Ms. Franchetta Stephens, Division of Toxicology, Agency for Toxic Substances and Disease Registry, Mailstop E-29, 1600 Clifton Road, NE, Atlanta, Georgia 30333, telephone (888) 422-8737 or (404) 498-0720.

SUPPLEMENTARY INFORMATION: The Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA) mandates that the Agency for Toxic Substances and Disease Registry (ATSDR) shall assess whether adequate information on health effects is available for the priority hazardous substances. Where such information is not available or under development, ATSDR shall, in cooperation with the National Toxicology Program, initiate a program of research to determine these health effects. The Act further directs that where feasible, ATSDR shall develop methods to determine the health effects of substances in combination with other substances with which they are commonly found. The Food Quality Protection Act (FQPA) of 1996 requires that factors to be considered in establishing, modifying, or revoking tolerances for pesticide chemical residues shall include the available information concerning the cumulative effects of substances that have a common mechanism of toxicity, and combined exposure levels to the substance and other related substances. The FQPA requires that the Administrator of the Environmental Protection Agency consult with the Secretary of the Department of Health and Human Services (which includes ATSDR) in implementing some of the provisions of the act.

To carry out these legislative mandates, ATSDR has developed a chemical mixtures program. As part of

the mixtures program, ATSDR developed a guidance manual that outlines the latest methods for mixtures health assessment. In addition, a series of documents called interaction profiles are being developed for certain priority mixtures that are of special concern to ATSDR. The purpose of an interaction profile is to evaluate data on the toxicology of the "whole" priority mixture (if available) and on the joint toxic action of the chemicals in the mixture in order to recommend approaches for the exposure-based assessment of the potential hazard to public health.

Although key studies for each of the mixtures were considered during the profile development process, this **Federal Register** notice seeks to solicit any additional studies, particularly unpublished data and ongoing studies, which will be evaluated for possible addition to the profiles now or in the future.

The following draft documents will be available to the public on or about, June 1, 2002.

Document 1

Guidance manual for the assessment of joint toxic action of chemical mixtures.

Document 2

Interaction profiles for persistent chemicals found in fish.
Chlorinated dibenzo-p-dioxins (CDDs), hexachlorobenzene, dichlorodiphenyl dichloroethane (p,p'-DDE), methyl mercury, and polychlorinated biphenyls (PCBs).

Document 3

Interaction profiles for persistent chemicals found in breast milk.
Chlorinated dibenzo-p-dioxins (CDDs), hexachlorobenzene, dichlorodiphenyl dichloroethane (p,p'-DDE), methyl mercury, and polychlorinated biphenyls (PCBs).

Document 4

Interaction profile for 1,1,1-trichloroethane, 1,1-dichloroethane, trichloroethylene, and tetrachloroethylene.

Document 5

Interaction profile for benzene, ethylbenzene, toluene, and xylenes (BTEX).

Document 6

Interaction profile for arsenic, cadmium, chromium, and lead.

Document 7

Interaction profile for copper, lead, manganese, and zinc.

All documents issued as "Drafts for Public Comment" represent ATSDR's best efforts to provide important toxicological information on interactions of priority hazardous

substances. We are seeking public comments and additional information which may be used to supplement these documents. ATSDR remains committed to providing a public comment period for these documents as a means to best serve public health and our clients.

Dated: May 24, 2002.

Georgi Jones,

Director, Office of Policy and External Affairs, Agency for Toxic Substances and Disease Registry.

[FR Doc. 02-13767 Filed 5-31-02; 8:45 am]

BILLING CODE 4310-70-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 01154]

Expansion of Prevention, Care and HIV/AIDS Surveillance Activities for Injection Drug Users With the Bangkok Metropolitan Administration, Bangkok, Thailand; Notice of Availability of Funds

Amendment

A notice announcing the availability of fiscal year (FY) 2001 funds for a cooperative agreement program for expansion of prevention, care and HIV/AIDS surveillance activities for injection drug users with the Bangkok Metropolitan Administration, Thailand, was published in the **Federal Register** on July 25, 2001, [Vol. 66, No. 143, Pages 38706-38707]. The notice is amended as follows:

On page 38706, First Column, Under Title, delete: "for Injection Drug Users."

On page 38706, First Column, Under Section A. Purpose, first paragraph, delete "among injection drug users (IDUs)."

On page 38706, First Column, Under Section A. Purpose, second paragraph, delete "among IDUs."

On page 38706, Third Column, Under Section C. Availability of Funds, Subsection Use of Funds, delete "Funds received from this announcement may not be used for the direct purchase of antiretroviral drugs for treatment of established HIV infection (with the exception of nevirapin in PMTCT cases and with prior written approval), occupational exposures, and non-occupational exposures and will not be used for the purchase of machines and reagents to conduct the necessary laboratory monitoring for patient care." and change to "The purchase of antiretrovirals, reagents, and laboratory equipment for antiretroviral treatment

projects requires pre-approval from the Global AIDS Program headquarters."

Dated: May 26, 2002.

Sandra R. Manning,

CGFM, Director, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 02-13781 Filed 5-31-02; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 01153]

Expansion of Prevention, Care and HIV/AIDS Surveillance With the Ministry of Public Health in the Kingdom of Thailand; Notice of Availability of Funds

Correction

A notice announcing the availability of fiscal year (FY) 2001 funds for a cooperative agreement program for expansion of prevention, care and HIV/AIDS surveillance with the Ministry of Public Health in the Kingdom of Thailand, was published in the **Federal Register** on July 16, 2001, [Vol. 66, No. 136, Pages 37036-37038]. The notice is corrected as follows:

On page 37038, First Column, Under Section C. Availability of Funds, remove: "Funds received from this announcement may not be used for the direct purchase of antiretroviral drugs for treatment of established HIV infection (with the exception of nevirapin in PMTCT cases and with prior written approval), occupational exposures, and non-occupational exposures and will not be used for the purchase of machines and reagents to conduct the necessary laboratory monitoring for patient care." and add in its place "The purchase of antiretrovirals, reagents, and laboratory equipment for antiretroviral treatment projects requires pre-approval from the Global AIDS Program headquarters."

On page 37038, First Column, Under Section E. Availability of Funds, remove: "1. Alterations and Renovations: Unallowable. 2. Customs and Import Duties: Unallowable. This includes consular fees, customs surtax, value added taxes, and other related charges."